72
Views
0
CrossRef citations to date
0
Altmetric
Review

Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

, ORCID Icon, &
Article: 1 | Received 16 Aug 2018, Accepted 14 Nov 2019, Published online: 04 Dec 2023

Reprints and Permissions

This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article in part or whole.